symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
PRFX,2.75,0.254171,453489,4285463,0,0.34-26.41,0.14,PainReform Ltd.,USD,0001801834,IL0011651580,M77798102,NASDAQ Capital Market,NASDAQ,Drug Manufacturersâ€”Specialty & Generic,https://www.painreform.com,"PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.","Mr. Ilan  Hadar M.B.A., MBA",Healthcare,IL,6,972 3 717 7050,65 Yigal Alon Street,Tel Aviv,,6745442,,0,https://financialmodelingprep.com/image-stock/PRFX.png,2020-09-01,False,False,True,False,False
